CLAIMS

What is claimed is:

1. ~~A method for treating vitiligo in a subject, comprising administering to the subject in need thereof a therapeutically effective amount~~ Use of 1-[(2S,5R)-2-methyl-5-(7H-pyrrolo[2,3-d]pyrimidin-4-ylamino)-1-piperidinyl]-2-propen-1-one or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for the treatment of vitiligo in a subject, wherein a therapeutically effective amount of the medicament is to be administered to the subject in need thereof.

2. The ~~method~~ use of claim 1, wherein the therapeutically effective amount is selected from the group consisting of 10, 30, 50, 100 or 200 mg QD.

3. The ~~method~~ use of any one of claims 1 to 2, wherein the ~~1-[(2S,5R)-2-methyl-5-(7H-pyrrolo[2,3-d]pyrimidin-4-ylamino)-1-piperidinyl]-2-propen-1-one or a pharmaceutically acceptable salt thereof~~medicament is to be administered to the subject for a maintenance period of up to 20 weeks following the induction period.

4. The ~~method~~ use of any one of claims 1 to 3, wherein the subject has a body surface area involvement fo 4- 50%.

5. The ~~method~~ use of any one of claims 1 to 3, wherein the subject achieves a percent change from baseline for local read facial Vitiligo Area Scoring Index of at least about -15%.

6. The ~~method~~ use of any one of claims 1 to 3, wherein the subject achieves a 75% reduction in F-VASI from baseline at week 24.

7. The ~~method~~ use of any one of claims 1 to 3, further comprising administering to the subject concurrent or subsequent treatment with narrow band ultraviolet B radiation add on therapy.

8. The ~~method~~ use of claim 7, wherein the narrow band ultraviolet B radiation add on therapy is to be administered for at least 24 weeks.

9. The ~~method~~ use of claim 7, whereby the subject achieves a percent change from baseline for local facial Vitiligo Area Scoring Index of up to between about -17% and about -30% at week 24 and between about -40% and about -80% at week 48.

10. The ~~method~~ use of any one of claims 1 to 9, wherein the therapeutically effective amount is 10 mg QD.

11. The ~~method~~ use according to any one of claims 1 to 9, wherein the therapeutically effective amount is 30 mg QD.

12. The ~~method~~ use of any one of claims 1 to 9, wherein the therapeutically effective amount is 50 mg QD.

13. The ~~method~~ use of any one of claims 1 to 9, wherein the therapeutically effective amount is 100 mg QD.

14. The ~~method~~ use of any one of claims 1 to 9, wherein the therapeutically effective amount during the induction period is 50mg QD.

15. The ~~method~~ use of any one of claims 1 to 9, wherein the therapeutically effective amount during the induction period is 100 mg QD.

16. Use of the compound 1-[(2S,5R)-2-methyl-5-(7H-pyrrolo[2,3-d]pyrimidin-4-ylamino)-1-piperidinyl]-2-propen-1-one, or a pharmaceutically acceptable salt thereof, for the preparation of a medicament for the treatment of vitiligo according to any one of claims 1 to 15.

17. The compound 1-[(2S,5R)-2-methyl-5-(7H-pyrrolo[2,3-d]pyrimidin-4-ylamino)-1-piperidinyl]-2-propen-1-one, or a pharmaceutically acceptable salt thereof, for use ~~in a method of treating~~in the treatment of vitiligo according to any one of claims 1 to 15.